Rheumatology Clinical Trials

The following searchable list includes all the Division of Rheumatology - Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.

Search Studies

Showing 1 to 10 of 14 entries

Previous1 2Next

Trials
Chicago Lupus Database Establishing in 1991 and maintained by Northwestern University, the Chicago Lupus Database (CLD) is a registry of individuals with lupus who are willing to be contacted about future lupus research studies for which they might be eligible. Participants can enroll in any number of research studies designed to help us … Establishing in 1991 and maintained by Northwestern University, the Chicago Lupus Database (CLD) is a registry of individuals with lupus who are willing to be contacted about future lupus research studies for which they might be eligible. Participants can enroll in any number of research studies designed to help us learn more about lupus. Eligibility Criteria Men and women 18 years or older with either a probable or definite lupus diagnosis can sign up for the Chicago Lupus Database. Principal Investigator Ramsey-Goldman, Rosalind Location(s) Map it 633 N. St. Clair St. Chicago, IL IRB number STU00009193 More Info Keywords lupus Email Milaeger, Holly Robin Phone +1 312 503 0251 Copy Study URL to Clipboard Copy
CPIRA-2 Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. Previous research has found that this ongoing pain may in part be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will … Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. Previous research has found that this ongoing pain may in part be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will identify factors that lead to the development of pain centralization, so that in future studies we can learn more about how to prevent the development of this kind of chronic pain in RA. Participants will complete a total of 3 study visits (baseline, 3 months and 12 months). At each study visit, participants will have a physical exam, have blood drawn, answer questionnaires, and undergo quantitative sensory testing to assess responses to pressure and coldness. A subset of patients who are interested and eligible will undergo a brain MRI at baseline and the 12-month study visit. Participants will receive $50 for the completion of each study visit and an additional $100 for completing each MRI. Eligibility CriteriaStudy participants must be 18 years or older with active Rheumatoid Arthritis and symptoms starting no more than one year prior to study participation. Participants taking pain medications must be on a stable dose for at least 3 months. Patients with Raynauds requiring treatment are not eligible to participate. Participants must refrain from taking prednisone (greater than 10 mg) or opioids within 24 hours of their study visit. Principal Investigator Lee, Yvonne Claire Location(s) Map it 710 N. Fairbanks Ct. Olson Pavilion Chicago, IL Map it 633 N. St. Clair St. Chicago, IL IRB number STU00211593 More Info Keywords Rheumatoid Arthritis Pain Email Langereis, Morgan Marguerite Phone 312 503 1187 Copy Study URL to Clipboard Copy
DAISY: Determine effectiveness of anifrolumab in systemic sclerosis We are doing this study to learn more about anifrolumab (SAPHNELOTM) in patients with systemic sclerosis and also to better understand the studied disease and associated health problems. Anifrolumab is being tested in research studies as a new treatment for systemic sclerosis and the purpose of this study is to … We are doing this study to learn more about anifrolumab (SAPHNELOTM) in patients with systemic sclerosis and also to better understand the studied disease and associated health problems. Anifrolumab is being tested in research studies as a new treatment for systemic sclerosis and the purpose of this study is to find out if anifrolumab is safe to use in systemic sclerosis and can improve the symptoms of the disease. Participants will be in the research study for approximately 122 weeks (2 years and 3 months). Participants are given an investigational drug and asked to come for approximately 16 study visits. For 52 weeks, half of the participants will receive 120 mg anifrolumab and half will receive placebo (inactive solution containing no anifrolumab) by injection under the skin (subcutaneous) while continuing to receive their standard therapies. Which study treatment you will be given will be randomly assigned. After 52 weeks, all participants will receive 120 mg anifrolumab (for 52 weeks) to evaluate the long-term safety of the study drug in patients with systemic sclerosis. Eligibility Criteria Between the ages of 18 and 70 Systemic sclerosis disease duration ≤ 6 years Stable, allowable immunosuppressant therapy Principal Investigator Moore, Duncan Location(s) Map it 675 N. Saint Clair St. Fourteenth Floor, Suite 100 Chicago, IL ClinicalTrials.gov IdentifierNCT05925803IRB number STU00219301 More Info Keywords sclerodema systemic sclerosis Copy Study URL to Clipboard Copy
IMPACT-Pain-RA Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. People living with RA commonly report persisting pain which on average is 30% more intense than the general population. Previous research has found that this ongoing pain may in part be … Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. People living with RA commonly report persisting pain which on average is 30% more intense than the general population. Previous research has found that this ongoing pain may in part be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will examine the relationship between immune cells (cells that are part of the immune system, that help the body fight infections and other diseases) and pain centralization. This study will also search for biomarkers (substances that can be measured in the blood) that may be associated with pain centralization, so that we can determine who may be at at risk for developing this kind of chronic pain and how to treat and/or prevent it in the future. Participants will be in this research study for one study visit, lasting about 2 hours. Participants will undergo a physical examination to assess joint inflammation, complete questionnaires, undergo quantitative sensory testing (QST) assessments, and provide blood samples. Eligibility Criteria Key Criteria: Meet the ACR/EULAR 1987 or 2010 criteria for RA On a DMARD for RA Swollen joint count ≤ 1 Principal Investigator Lee, Yvonne Claire Location(s) Map it 633 N. St. Clair St. Chicago, IL IRB number STU00215712 More Info Keywords rheumatoid arthritis pain RA Email Galarce Lugo, Gelis Enid Phone 312 503 8325 Copy Study URL to Clipboard Copy
LIFT: Lupus Intervention for Fatigue Trial This study is designed to evaluate the effectiveness of one-on-one counseling sessions on reducing symptoms of fatigue in persons with lupus by providing them with individualized coaching on increasing physical activity and improving diet. Eligibility CriteriaHave lupus and experience fatigue as a result. At least 18 years old. Can participate in physical activity. Live in the Chicago area. Be able to speak and read English. Be able to consent to being in the study. Principal Investigator Ramsey-Goldman, Rosalind Location(s) Map it 633 N. St. Clair St. Chicago, IL ClinicalTrials.gov IdentifierNCT02653287IRB number STU00201960 More Info Keywords Lupus diet physical activity behavior Email Milaeger, Holly Robin Phone +1 312 503 3904 Copy Study URL to Clipboard Copy
Molecular Biomarkers to Guide Therapy in the Systemic Sclerosis-Associated Interstitial Lung Disease The purpose of this study is to better understand the development and progression of scleroderma-related lung fibrosis (SSc-ILD). We would like to find indicators (biomarkers) that can help us predict which patients will develop SSc-ILD and who might benefit from receiving certain treatments. To do this, we … The purpose of this study is to better understand the development and progression of scleroderma-related lung fibrosis (SSc-ILD). We would like to find indicators (biomarkers) that can help us predict which patients will develop SSc-ILD and who might benefit from receiving certain treatments. To do this, we will collect and study your clinical and imaging data and samples (blood, lung fluid, and skin) if you agree to participate in this research. Eligibility Criteria SSc Patients Inclusion Criteria: Age 18 or older Receiving clinical care at Northwestern Medicine Meet 2013 ACR criteria for diagnosis of SSc Exclusion Criteria: Unable to provide informed consent Diagnosis of an overlap syndrome (i.e., SLE, RA, etc.) that is considered clinically significant by the investigators Currently pregnant or nursing Contraindication to the bronchoscopy per the pulmonologist Healthy Controls Inclusion Criteria: Age 18 or older Not diagnosed with a rheumatic autoimmune disease (i.e., lupus (SLE), rheumatoid arthritis (RA), etc.) Exclusion Criteria: Unable to provide informed consent Currently pregnant or nursing Current smoker or former smoker (> 10 pack years) Lung disease, uncontrolled congestive heart failure, cancer or history of cancer, HIV, or chronic liver disease Contraindication to the bronchoscopy per the pulmonologist Principal Investigator Misharin, Alexander Location(s) Map it 675 N. Saint Clair St. Eighteenth Floor, Suite 250 Chicago, IL Map it 675 N. Saint Clair St. Fourteenth Floor, Suite 100 Chicago, IL IRB number STU00218939 More Info Keywords systemic sclerosis SSc SSc-ILD interstitial lung disease Email Soriano, Alexandra Phone +1 312 503 1120 Copy Study URL to Clipboard Copy
Northwestern Scleroderma Program Registry The Scleroderma Patient Registry collects clinical information and biological samples for patients seen at the Northwestern Scleroderma Program (NSP). The information collected is used for studies designed to increase our understanding about the course of the disease and the care and outcomes of scleroderma patients. Researchers conduct studies to learn … The Scleroderma Patient Registry collects clinical information and biological samples for patients seen at the Northwestern Scleroderma Program (NSP). The information collected is used for studies designed to increase our understanding about the course of the disease and the care and outcomes of scleroderma patients. Researchers conduct studies to learn more about scleroderma, understand why the skin and other internal organs become thickened and hardened (fibrotic) in people with scleroderma, and determine what therapies are effective for treating scleroderma. The registry also allows us to identify possible patients for future studies related to scleroderma. There are five optional components of the Registry: completion of health questionnaires, skin biopsies at two different time points, annual blood collection, and participation in NUgene. Eligibility CriteriaPatients ≥18 years old with a diagnosis of scleroderma (including all sub-types of disease) as defined by American College of Rheumatology criteria or scleroderma mimic disorder, localized scleroderma, or very early diagnosis of systemic sclerosis (VEDOSS), per physician assessment. Principal Investigator Richardson, Carrie Location(s) Map it 633 N. St. Clair St. Chicago, IL IRB number STU00002669 More Info Keywords scleroderma skin fibrosis systemic sclerosis autoimmune Email Soriano, Alexandra Phone +1 312 503 1120 Copy Study URL to Clipboard Copy
NP-SLE This study will examine different proteins and cell types in blood and cerebrospinal fluid (CSF) of patients with systemic lupus (SLE) who may or may not currently be experiencing neuropsychiatric manifestations of the disease. We aim to identify specific factors that affect the regulation of genes to help explain what … This study will examine different proteins and cell types in blood and cerebrospinal fluid (CSF) of patients with systemic lupus (SLE) who may or may not currently be experiencing neuropsychiatric manifestations of the disease. We aim to identify specific factors that affect the regulation of genes to help explain what goes wrong in systemic lupus. Then, we hope to develop treatments that will target these factors. Eligibility Criteria Inclusion Criteria: Meet 4 of 11 American College of Rheumatology (ACR) criteria for systemic lupus (SLE) or meet 3 of 11 ACR criteria for SLE and meet SLICC criteria 18 years or older Positive ANA or positive dsDNA Exclusion Criteria: Currently pregnant or nursing Active or chronic infections (such as hepatitis, pneumonia, pyelonephritis, HIV, sepsis) Diagnosed with another chronic autoimmune disease or chronic neurodegenerative condition CKD > 2 and/or GFR < 60 AST and/or ALT ≥ 3 times the upper limit of normal Current electrolyte disturbance (hyponatremia or hypernatremia) Current signs or symptoms of acute systemic vascultis Principal Investigator Cuda, Carla Marie Location(s) Map it 675 N. Saint Clair St. Fourteenth Floor, Suite 100 Chicago, IL IRB number STU00211615 More Info Keywords lupus systemic lupus erythematosus SLE NPSLE neuropsychiatric systemic lupus erythematosus Email Safdar, Komel Phone Copy Study URL to Clipboard Copy
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis The purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, … The purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, macrophages produce proteins that activate the immune system to assist in tissue repair. However, there is evidence that in people with scleroderma, the macrophages behave abnormally and contribute to scarring in the lungs. Patients who participate in this study will: donate fluid collected from their lungs during a bronchoscopy (taken at the time they are already scheduled to have a bronchoscopy or during their scheduled endoscopy) give a blood sample give esophageal biopsies (taken during their scheduled endoscopy) as an option, give skin biopsies Eligibility Criteria At least 18 years old Meet criteria for systemic sclerosis Receive care at Northwestern Medicine in Rheumatology, Pulmonary & Critical Care, and/or Gastroenterology scleroderma clinics Plan to undergo a standard of care bronchoscopy or endoscopy at Northwestern or a research bronchoscopy through a separate Northwestern study Principal Investigator Perlman, Harris R Location(s) Map it 633 N. St. Clair St. Chicago, IL IRB number STU00207083 More Info Keywords systemic sclerosis scleroderma interstitial lung disease ILD SSc-ILD fibrosis SSc endoscospy bronchoscopy Email Soriano, Alexandra Phone +1 312 503 4958 Copy Study URL to Clipboard Copy
PROMOTER Finding a way to reduce pain is consistently named one of the top priorities for patients with RA. People living with RA commonly report persisting pain which, on average, is 30% more intense than the general population. Previous research has found that this ongoing pain may, in part, be caused … Finding a way to reduce pain is consistently named one of the top priorities for patients with RA. People living with RA commonly report persisting pain which, on average, is 30% more intense than the general population. Previous research has found that this ongoing pain may, in part, be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will identify factors associated with pain centralization, so that, in future studies, we can learn more about how to prevent the development of chronic pain in RA. This study will also identify biomarkers that could provide insight into targeted therapies for future clinical trials. This study includes two in-person study visit to complete quantitative sensory testing (QST), blood draws, joint counts, blood pressure assessment, and patient-reported outcome (PRO) questionnaires. If participants are unsure of their height and/or weight off-at the time of the visits, they may also have height and/or weight assessed. The first visit will occur at baseline within 3 weeks of the patient starting their DMARD. The second visit will occur 12 weeks (+/- 3 weeks) after starting their new DMARD. Eligibility Criteria Key Eligibility Criteria Have had at least one joint with definite swelling Meet the ACR/EULAR 1987 or 2010 criteria for RA Starting a DMARD for treatment of active RA Principal Investigator Lee, Yvonne Claire IRB number STU00216431 More Info Keywords rheumatoid arthritis pain Email Langereis, Morgan Marguerite Phone 312 503 1187 Copy Study URL to Clipboard Copy